Todays Report: The Stillwater Capital Advisors LLC Boosts Position in CVS Health Corporation (CVS)

The Stillwater Capital Advisors LLC Boosts Position in CVS Health Corporation (CVS)

Stillwater Capital Advisors LLC boosted its position in CVS Health Corporation (NYSE:CVS) by 32.6% during the third quarter, Holdings Channel reports. The fund owned 115,061 shares of the pharmacy operator’s stock after buying an additional 28,289 shares during the period. CVS Health Corporation comprises approximately 3.0% of Stillwater Capital Advisors LLC’s investment portfolio, making the stock its 17th largest position. Stillwater Capital Advisors LLC’s holdings in CVS Health Corporation were worth $10,239,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of CVS. Acrospire Investment Management LLC increased its stake in shares of CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock valued at $102,000 after buying an additional 900 shares during the period. MU Investments Co. Ltd. increased its stake in shares of CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock valued at $109,000 after buying an additional 440 shares during the period. Pinkerton Retirement Specialists LLC increased its stake in shares of CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock valued at $110,000 after buying an additional 1,112 shares during the period. D Orazio & Associates Inc. increased its stake in shares of CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 100 shares during the period. Finally, Cantab Capital Partners LLP increased its stake in shares of CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock valued at $113,000 after buying an additional 924 shares during the period. 81.78% of the stock is currently owned by institutional investors.

Shares of CVS Health Corporation (NYSE:CVS) traded up 0.53% during trading on Friday, hitting $74.06. The stock had a trading volume of 3,529,190 shares. The company has a market cap of $78.98 billion, a PE ratio of 15.87 and a beta of 0.88. The stock has a 50 day moving average of $81.80 and a 200 day moving average of $91.85. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $106.67.

CVS Health Corporation (NYSE:CVS) last released its earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.07. The firm had revenue of $44.60 billion for the quarter, compared to analysts’ expectations of $45.29 billion. CVS Health Corporation had a return on equity of 17.18% and a net margin of 2.96%. The company’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.28 earnings per share. Equities analysts forecast that CVS Health Corporation will post $5.81 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th were paid a dividend of $0.425 per share. The ex-dividend date of this dividend was Thursday, October 20th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 2.30%. CVS Health Corporation’s dividend payout ratio is 36.40%.

A number of research analysts have issued reports on CVS shares. Leerink Swann restated a “buy” rating and issued a $105.00 price objective on shares of CVS Health Corporation in a research note on Wednesday, November 9th. Morgan Stanley restated a “hold” rating and issued a $104.00 price objective on shares of CVS Health Corporation in a research note on Monday, September 12th. Deutsche Bank AG restated a “hold” rating and issued a $99.00 price objective (down previously from $108.00) on shares of CVS Health Corporation in a research note on Tuesday, October 18th. Guggenheim restated a “buy” rating and issued a $90.00 price objective (down previously from $115.00) on shares of CVS Health Corporation in a research note on Tuesday, November 8th. Finally, Argus restated a “buy” rating and issued a $85.00 price objective (down previously from $120.00) on shares of CVS Health Corporation in a research note on Thursday, November 10th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $106.24.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment